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All reagents and solvents were purchased from Acros Organics, Aldrich, Fisher Scientific, Iris Biotech 
and Novabiochem. Dichloromethane was dried under reflux over calcium hydride. Glass slides for 
fluoresce microscopy were obtained from Ibidi (Cat# 80827). TEM grids (i. Cu carbon type-B, 300 
mesh; ii. Holey carbon, 400 mesh) and PELCO® mica discs for AFM were purchased from Ted Pella. 
 
2. Instrumentation 
Peptide purification was carried out by preparative reverse-phase HPLC (Waters 1525 and 2489) 
using an Agilent Eclipse XDB-C18 column. 1H-NMR spectra were acquired on Varian 300 or 500 MHz 
spectrometers at 298K; chemical shifts (δ) are reported in ppm relative to that of DMSO (δ = 2.50 
ppm). Analytical UHPLC of the peptide was performed on an Agilent 1260 Infinity II fitted with an 
Agilent SB-C18 column and connected to a 6120 quadrupole MS detector. HR-MS was acquired on a 
Bruker MicroTOF. FT-IR spectra were acquired on a PerkinElmer Spectrum II fitted with an ATR. 
Epifluorescence micrographs were taken with a Nikon Eclipse Ti (60x immersion objective, FITC 
cube: Ex=475/35 nm; Em=530/43 nm). STEM images were acquired on a FESEM Ultra plus (Zeiss) 
operating at 20 kV from unstained samples. Non-contact mode AFM analysis was performed on a 
NX-10 instrument fitted with ACTA 10M cantilevers (Park systems). Cross-polarised microscopy was 
performed on an Olympus BX51 fitted with two rotary polarisers. Wide-angle X-ray scattering 
(WAXS) was measured on a Bruker D8 VENTURE PHOTON-III 14 κ-geometry diffractometer fitted 
with an Incoatec IμS 3.0 microfocus sealed tube (Cu Kα, λ = 1.54178 Å) and a multilayer mirror 
monochromator. Circular dichroism spectra were recorded on a Jasco J-1100 CD spectrometer from 
a 2 mm quartz cuvette. Fluorescence spectra were acquired on a Varian Cary Eclipse from a 1 cm 
quartz cuvette. Dynamic light scattering (DLS) data was acquired on a Zetasizer Nano ZSP (Malvern). 
 
3. Abbreviations 
AcCN: acetonitrile; DCM: dichloromethane; DIPEA: N,N-diisopropylethylamine; DMF: N,N-
dimethylformamide; DMSO: dimethyl sulfoxide; FITC: fluorescein isothiocyanate; Fmoc: 9-
fluorenylmethyloxycarbonyl; HBTU: N,N,Nʹ,Nʹ-tetramethyl-O-(1H-benzotriazol-1-yl)uranium 
hexafluorophosphate; PyAOP: (7-azabenzotriazol-1-yloxy)trispyrrolidinophosphonium 




4. Synthesis and purification of cyclic peptides 
 
  
Scheme S1 a) Rink amide resin functionalisation: i) Piperidine 20% v/v in DMF, 30 min; ii) Fmoc-L-
Glu-OAll, HBTU, DIPEA, DMF, 1h. b) Peptide elongation: i) Piperidine 20% v/v in DMF, 15 min; ii) 
amino acid, HBTU, DIPEA, DMF, 30 min; Repeat 7 cycles with the corresponding amino acids. c) i) 
OAllyl removal: Pd(OAc)2, PPh3, phenylsilane, 4-methylmorpholine, DCM, overnight; ii) Fmoc 
removal: Piperidine 20% v/v in DMF, 30 min; iii) Peptide cyclisation: PyAOP, DIPEA, DMF, overnight; 















































































Detailed synthetic protocol: 
Fmoc-Rink amide SPPS resin (135.0 mg, 0.1 mmol) was swollen in DMF for 30 min and the Fmoc 
group removed by treatment with piperidine 20% v/v in DMF (2 mL) for 30 min. The resin was then 
washed and treated with Fmoc-L-Glu(OH)-OAll (163.6 mg, 0.4 mmol), HBTU (151.5 mg, 0.4 mmol) 
and DIPEA (105 µL, 0.6 mmol) in DMF (2 mL) for 1 h. After this time, we followed cycles of Fmoc 
removal (2 mL of piperidine 20% v/v in DMF for 15 min) and amino acid coupling (0.4 mmol of 
amino acid, 0.4 mmol of HBTU, 0.6 mmol of DIPEA in 2 mL of DMF for 30 min) until all amino acids 
were coupled, leaving the N-terminal Fmoc group still on the peptide. 
For OAllyl removal, the resin was thoroughly washed with DMF and DCM, and then reacted with 2 
mL of a pre-mixed cocktail of Pd(OAc)2 (6.7 mg, 0.03 mmol), PPh3 (39.3 mg, 0.15 mmol), 4-
methylmorpholine (110 µL, 1.0 mmol) and phenylsilane (123 µL, 1.0 mmol) in dry DCM overnight. 
The resin was then filtered and washed with DCM, 10 mL of DIPEA 2% v/v in DMF, DMF, and then 
twice with 2 mL of 0.5% m/m diethyldithiocarbamate in DMF for 30 min to remove all traces of Pd. 
For N-terminal Fmoc removal, the resin was reacted with 2 mL of piperidine 20% v/v in DMF for 30 
min and then washed with DMF. 
The peptide was then cyclised by reacting the resin with PyAOP (208.4 mg, 0.4 mmol) and DIPEA 
(105 µL, 0.6 mmol) in 2 mL of DMF for 2 hours. This step was repeated twice more. 
Once cyclised, the resin was washed with DMF and DCM, and the peptide was cleaved from the 
resin by treatment with 2 mL of TFA (90% v/v), DCM (5% v/v), H2O (2.5% v/v) and TIPS (2.5% v/v) for 
2 h. After this time, the acidic solution was filtered and concentrated under a flow of nitrogen, to 
be then precipitated into 45 mL of chilled diethyl ether. The suspension thus obtained was 
centrifuged (3 krcf, 10 min) and the pellet dissolved in a 1:1 mixture of H2O:AcCN and purified by 
preparative reverse-phase HPLC (A = H2O + 0.1% v/v TFA; B = AcCN + 0.1% v/v TFA; 15 mL·min-1): 0 
min (0% B) à 5 min (0% B) à 30 min (75% B) à 35 min (95% B) à 40 min (95% B); Rt = 19.9 min. 
Peptide fractions were concentrated in vacuo to remove TFA and AcCN, and the remaining aqueous 
solution was freeze dried. 
A white powder was thus obtained: CPx (30 mg; 28% yield), CPxAla (15 mg; 15% yield), CPx-Glu (37 
mg; 35% yield) and CPx-His (22 mg; 21% yield).  
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5. CPx characterisation 
5.1. 1H-NMR (300 MHz, DMSO-d6) d = 0.64-1.31 (m, 18H, Leu i-Bu x2), 1.55-2.12 (m, 12H, Glu -CH2- 
x2 + Gln -CH2-), 2.80-3.11 (m, 6H, His -CH2- x2 + Trp -CH2-), 4.27-4.49 (m, 5H, Ha), 4.62-4.85 (m, 3H, 
Ha), 6.76 (s, 1H, Gln-CONH2), 6.93 (t, J = 7.3 Hz, 1H, Trp), 7.02 (t, J = 7.3 Hz, 1H, Trp), 7.11 (d, J = 2.4 
Hz, 1H, Trp), 7.22 (s, 1H, Gln-CONH2), 7.28 (d, J = 8.1 Hz, 1H, Trp), 7.33 (d, J = 13.5 Hz, 2H, His x2), 
7.68 (d, J = 7.8 Hz, 1H, Trp), 8.04 (d, J = 8.7 Hz, 1H, CONH), 8.10 (d, J = 8.3 Hz, 1H, CONH), 8.17 (d, J = 
8.2 Hz, 1H, CONH), 8.26 (d, J = 7.9 Hz, 1H, CONH), 8.32 (d, J = 8.3 Hz, 1H, CONH), 8.38 (d, J = 8.3 Hz, 
1H, CONH), 8.40 (d, J = 8.2 Hz, 1H, CONH), 8.46 (d, J = 8.7 Hz, 1H, CONH), 8.96 (dd, J = 11.9, 1.3 Hz, 
2H, His x2), 10.79 (d, J = 2.2 Hz, 1H, Trp-NH) ppm. 
 
 




















































5.2. UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% v/v TFA; B = AcCN + 0.1% v/v TFA; 0.35 mL·min-1: 0 
min (0% B) à 2 min (0% B) à 21 min (75% B) à 22 min (95% B); Rt = 12.5 min. m/z = 1,073.4 
([M+H]+), 537.3 ([M+2H]2+). 
 




5.3. HR-MS (ESI, +eV) m/z = 1073.5163 (calculated for [M+H]+) 1073.5162 (found). 




6. CPxAla characterisation 
6.1. 1H-NMR (300 MHz, DMSO-d6) d = 0.94 (t, J = 6.6 Hz, 6H, Ala 
x2), 1.56-2.12 (m, 12H, Glu -CH2- x2 + Gln -CH2-), 2.80-3.09 (m, 
6H, His -CH2- x2 + Trp -CH2-), 4.25-4.45 (m, 5H, Ha), 4.52-4.60 (m, 
1H, Ha), 4.69-4.79 (m, 2H, Ha), 6.77 (s, 1H, Gln-CONH2), 6.94 (t, J 
= 7.4 Hz, 1H, Trp), 7.03 (t, J = 7.3 Hz, 1H, Trp), 7.12 (d, J = 2.3 Hz, 
1H, Trp), 7.22 (s, 1H, Gln-CONH2), 7.29 (d, J = 7.7 Hz, 1H, Trp), 
7.32 (d, J = 12.7 Hz, 2H, His x2), 7.62 (d, J = 7.7 Hz, 1H, Trp), 8.11 
(d, J = 8.3 Hz, 2H, CONH), 8.17 (d, J = 8.3 Hz, 1H, CONH), 8.24-
8.31 (m, 4H, CONH), 8.43 (d, J = 8.4 Hz, 1H, CONH), 8.95 (d, J = 5.4 Hz, 2H, His x2), 10.78 (s, 1H, Trp-
NH) ppm. 




































































6.2. UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% v/v TFA; B = AcCN + 0.1% v/v TFA; 0.35 mL·min-1: 0 
min (0% B) à 2 min (0% B) à 21 min (75% B) à 22 min (95% B); Rt = 9.9 min. m/z = 989.4 ([M+H]+), 
495.4 ([M+2H]2+). 
 




6.3. HR-MS (ESI, +eV) m/z = 989.4224 (calculated for [M+H]+) 989.4228 (found). 
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7. CPx-Glu characterisation 
7.1. 1H-NMR (500 MHz, DMSO-d6) d = 0.69-1.26 (m, 18H, Leu i-
Bu x2), 1.58-2.11 (m, 12H, Gln -CH2- x3), 2.84-3.11 (m, 6H, His -
CH2- x2 + Trp -CH2-), 4.20-4.44 (m, 5H, Ha), 4.62-4.81 (m, 3H, 
Ha), 6.74 (s, 1H, Gln-CONH2), 6.80 (s, 2H, Gln-CONH2 x2), 6.93 (t, 
J = 7.7 Hz, 1H, Trp), 7.01 (t, J = 8.0 Hz, 1H, Trp), 7.11 (d, J = 2.7 Hz, 
1H, Trp), 7.22 (s, 2H, Gln-CONH2 x2), 7.24 (s, 1H, Gln-CONH2), 
7.28 (d, J = 8.0 Hz, 1H, Trp), 7.32 (d, J = 16.8 Hz, 2H, His x2), 7.66 
(d, J = 7.9 Hz, 1H, Trp), 8.01 (d, J = 8.5 Hz, 1H, CONH), 8.09 (d, J = 
8.4 Hz, 1H, CONH), 8.15 (d, J = 8.3 Hz, 1H, CONH), 8.28 (d, J = 8.6 Hz, 1H, CONH), 8.29 (d, J = 8.3 Hz, 
1H, CONH), 8.33 (d, J = 8.5 Hz, 1H, CONH), 8.37 (d, J = 8.0 Hz, 1H, CONH), 8.47 (d, J = 8.7 Hz, 1H, 
CONH), 8.95 (dd, J = 18.5, 1.3 Hz, 2H, His x2), 10.79 (s, 1H, Trp-NH) ppm.  
 






















































7.2. UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% v/v TFA; B = AcCN + 0.1% v/v TFA; 0.35 mL·min-1: 0 
min (0% B) à 2 min (0% B) à 21 min (75% B) à 22 min (95% B); Rt = 11.9 min. m/z = 1071.6 
([M+H]+), 536.4 ([M+2H]2+). 
 




6.3. HR-MS (ESI, +eV) m/z = 1071.5483 (calculated for [M+H]+) 1071.5481 (found). 
 
Figure S9 High resolution mass spectrometry (HR-MS) analysis of CPx-Glu. 
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8. CPx-His characterisation 
8.1. 1H-NMR (500 MHz, DMSO-d6:TFA [8:1]) d = 0.69-0.88 (m, 
12H, Leu -CH3 x4), 1.33 -1.56 (m, 6H, Leu -CH2CH- x2), 1.73-2.24 
(m, 20H, Gln + Glu -(CH2)2- x5), 2.90-3.16 (m, 2H, Trp -CH2-), 
4.06-4.72 (m, 8H, Ha), 6.93 (t, J = 7.9 Hz, 1H, Trp), 6.99-7.03 
(m, 1H, Trp), 7.13 (d, J = 15.6 Hz, 1H, Trp), 7.28 (d, J = 8.5 Hz, 
1H, Trp), 7.66 (t, J = 9.5 Hz, 1H, Trp), 7.91-8.44 (m, 8H, CONH), 
10.74 (s, 1H, Trp-NH) ppm.  
 
 













































8.2. UHPLC-MS (C18-ESI, +eV) A = H2O + 0.1% v/v TFA; B = AcCN + 0.1% v/v TFA; 0.35 mL·min-1: 0 
min (0% B) à 2 min (0% B) à 21 min (75% B) à 22 min (95% B); Rt = 12.9 min. m/z = 1055.6 
([M+H]+), 528.4 ([M+2H]2+). 
 
Figure S11 Reverse-phase UHPLC (left) and mass spectrum of the peak in the chromatogram (right) 
of CPx-His. 
 
6.3. HR-MS (ESI, +eV) m/z = 1055.5156 (calculated for [M+H]+) 1055.5153 (found). 
 
Figure S12 High resolution mass spectrometry (HR-MS) analysis of CPx-His. 
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9. Epifluorescence microscopy of CPx nanosheets 
 







10. Scanning-transmission electron microscopy (STEM) of CPx nanosheets 
 
Figure S14 Scanning-transmission electron microscopy (STEM) of damaged CPx nanosheets. Aligned 
nanotubes can be found only on defined areas of the grid next to remaining sheet fragments (see 





11. Sonication of CPx nanosheets: Epifluorescence and electron microscopy 
 
Figure S15 Scanning-transmission electron microscopy (STEM) of sonicated CPx nanosheets 







Figure S16 Epifluorescence micrographs of CPx nanosheets after sonication (left) and that same 






12. Annealing of CPx nanosheets: Electron microscopy 
 
 
Figure S17 Scanning-transmission electron microscopy (STEM) of CPx samples (100 µM) heated at 





13. Annealing of CPx nanosheets: Dynamic light scattering (DLS) 
 
Figure S18 Dynamic light scattering (DLS) characterisation of CPx samples (100 µM) at 80°C and 



































Figure S19 Effect of CPx concentration on nanosheet assembly. Epifluorescence micrographs of CPx 













Figure S20 Effect of temperature on nanosheet assembly. Epifluorescence micrographs of CPx 
samples (100 µM) annealed at different temperatures (see insets). R.T. = Room temperature. Scale 










15. Atomic force microscopy (AFM) of CPx nanosheets at pH 2.8 
 
Nanosheet height at pH 2.8 (Figure S22) matches that observed at pH 7.4 (Figure 4a). 
 
 
Figure S21 Atomic force micrographs and height profiles of CPx nanosheets annealed (i. 80°C /1.5 




16. Dynamic behaviour of CPx nanosheets in response to pH and temperature 
 
Figure S22 Epifluorescence micrographs of CPx solutions (100 µM) sequentially adjusted between 
pH 6.0 and 7.4. All samples underwent a heating-cooling cycle (i. 80°C /1.5 h; ii. R.T./1 h) before 




17. FT-IR analysis of CPx nanosheets 
 
Figure S23 FT-IR spectrum of CPx nanosheets. Bands corresponding to the H-bonded backbones of 
cyclic peptides as β-sheets are indicated with a black line between the spectrum and their 
wavenumber. The sample was drop-cast (5x 10 µL) and dried on the ATR crystal for analysis. 
 
 
18. Circular dichroism (CD) analysis of CPx nanosheets 
 
Figure S24 Circular dichroism (CD) spectrum of CPx nanosheets (100 µM) at a pH of 7.4 recorded at 




























































Figure S25 Epifluorescence micrographs of CPxAla solutions (100 µM) prepared in 20 mM 
phosphate buffer at pH 7.4. Samples underwent a heating-cooling cycle (i. 80°C /1.5 h; ii. R.T./1 h) 







Figure S26 Epifluorescence micrographs of CPx-Glu solutions (100 µM) prepared in 20 mM 
phosphate buffer at pH 7.4. Samples underwent a heating-cooling cycle (i. 80°C /1.5 h; ii. R.T./1 h) 








Figure S27 Epifluorescence micrographs of CPx-His solutions (100 µM) prepared in 20 mM 
phosphate buffer at pH 7.4. Samples underwent a heating-cooling cycle (i. 80°C /1.5 h; ii. R.T./1 h) 
before imaging. Scale bars = 50 µm. 
 
